XML 64 R46.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Income Taxes (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Schedule of Income Before Income Taxes |
a. | Income (loss) before income taxes:
|  | Year ended December 31, |
|  | 2024 |  |  | 2023 |  |  | 2022 |
|  | (U.S. $ in millions) |
Parent Company and its Israeli subsidiaries |  | $ | (456 | ) |  | $ | (767 | ) |  | $ | (119 | )
Non-Israeli subsidiaries |  |  | (828 | ) |  |  | 143 |  |  |  | (3,044 | )
|  | $ | (1,284 | ) |  | $ | (624 | ) |  | $ | (3,163 | )
Schedule of the Provision for Income Taxes | b. Income taxes:
|  | Year ended December 31, |
|  | 2024 |  |  | 2023 |  |  | 2022 |
|  | (U.S. $ in millions) |
In Israel |  | $ | 721 |  |  | $ | (402 | ) |  | $ | 33 |
Outside Israel |  |  | (45 | ) |  |  | 395 |  |  |  | (676 | )
|  | $ | 676 |  |  | $ | (7 | ) |  | $ | (643 | )
Current |  | $ | 1,094 |  |  | $ | 333 |  |  | $ | 430 |
Deferred |  |  | (418 | ) |  |  | (340 | ) |  |  | (1,073 | )
|  | $ | 676 |  |  | $ | (7 | ) |  | $ | (643 | )
Accumulated Other Comprehensive Income/(Loss) (Net of Tax) |
|  | 2024 |  |  | 2023 |  |  | 2022 |
|  | (U.S. $ in millions) |
Income (loss) before income taxes |  | $ | (1,284 | ) |  | $ | (624 | ) |  | $ | (3,163 | )
Statutory tax rate in Israel |  |  | 23 | % |  |  | 23 | % |  |  | 23 | %
Theoretical provision for income taxes |  | $ | (295 | ) |  | $ | (144 | ) |  | $ | (727 | )
Increase (decrease) in the provision for income taxes due to: |  |  |  |  |  |  |  |  |  |  |  |
Tax benefits arising from net deferred taxes, resulting from intellectual property related integration plans, including carryforward losses |  |  | (87) |  |  |  | (272) |  |  |  | — |
The Parent Company and its Israeli subsidiaries - Settlement with the Israeli tax authorities |  |  | 514 |  |  |  | — |  |  |  | — |
Increase (decrease) in other uncertain tax positions - net |  |  | 171 |  |  |  | — |  |  |  | — |
Tax benefits arising from reduced tax rates under benefit programs |  |  |  |  |  |  | 14 |  |  |  | 15 |
Mainly nondeductible items and prior year tax |  |  | 16 |  |  |  | — |  |  |  | 35 |
Non-Israeli subsidiaries |  |  |  |  |  |  |  |  |  |  |  |
Impairments that did not have a corresponding tax effect, non-deductible interest and other items |  |  | 463 |  |  |  | 372 |  |  |  | 941 |
Adjustments to valuation allowances on deferred tax assets (*) |  |  | (105) |  |  |  | — |  |  |  | — |
Worthless stock deduction (**) |  |  |  |  |  |  | — |  |  |  | (909 | )
Increase (decrease) in other uncertain tax positions - net |  |  | (1 | ) |  |  | 23 |  |  |  | 2 |
Effective consolidated income taxes |  | $ | 676 |  |  | $ | (7 | ) |  | $ | (643 | )
* | Mainly related to deduction of interest expenses in the United States.
** | In 2022, one of Teva’s U.S. subsidiaries was determined to be insolvent for tax purposes (i.e., its liabilities exceeded the fair market value of its assets), mainly in light of its accumulated operational losses. Consequently, Teva recognized on its 2022 tax return, a worthless stock deduction of approximately $4.2 billion, with a related tax benefit of approximately $909 million.
Schedule of Deferred Income Taxes |
c. | Deferred income taxes:
|  | December 31, |
|  | 2024 |  |  | 2023 |
|  | (U.S. $ in millions) |
Deferred tax assets (liabilities), net: |  |  |  |
Inventory related |  | $ | 88 |  |  | $ | 76 |
Sales reserves and allowances |  |  | 55 |  |  |  | 81 |
Provision for legal settlements |  |  | 667 |  |  |  | 702 |
Intangible assets (*) |  |  | 170 |  |  |  | (118 | )
Carryforward losses and deductions and credits (**) |  |  | 1,557 |  |  |  | 2,463 |
Property, plant and equipment |  |  | (157 | ) |  |  | (225 | )
Deferred interest |  |  | 789 |  |  |  | 799 |
Provisions for employee related obligations |  |  | 95 |  |  |  | 80 |
Other (***) |  |  | 69 |  |  |  | 357 |
|  |  | 3,333 |  |  |  | 4,215 |
Valuation allowance—in respect of carryforward losses and deductions that may not be utilized |  |  | (2,017 | ) |  |  | (3,009 | )
|  | $ | 1,316 |  |  | $ | 1,206 |
(*) | The increase in deferred tax is mainly due to intellectual property related integration.
(**) | The amounts are shown after reduction for unrecognized tax benefits of $163 million and $2 million as of December 31, 2024 and 2023, respectively.
The amount as of December 31, 2024 represents the tax effect of gross carryforward losses and deductions with the following expirations: 2025 - 2026 —$38 million; 2027 - 2034 —$486 million; 2035 and thereafter—$38 million. The remaining balance—$995 million—can be utilized with no expiration date.
(***) | The amounts shown for 2023 are primarily comprised of Capitalization of R&D Expenses.
Schedule of Deferred Tax Assets and Liabilities By Report Caption | The deferred income taxes are reflected in the balance sheets among:
|  | December 31, |
|  | 2024 |  |  | 2023 |
|  | (U.S. $ in millions) |
Long-term assets—deferred income taxes |  |  | 1,799 |  |  |  | 1,812 |
Long-term liabilities—deferred income taxes |  |  | (483 | ) |  |  | (606 | )
|  | $ | 1,316 |  |  | $ | 1,206 |
Schedule of Unrecognized Tax Benefits |
d. | Uncertain tax positions:
The following table summarizes the activity of Teva’s gross unrecognized tax benefits:
|  | Year ended December 31, |
|  | 2024 |  |  | 2023 |  |  | 2022 |
|  | (U.S. $ in millions) |
Balance at the beginning of the year |  | $ | 651 |  |  | $ | 638 |  |  | $ | 672 |
Increase (decrease) related to prior year tax positions, net |  |  | 109 |  |  |  | (1 | ) |  |  | (46 | )
Increase related to current year tax positions |  |  | 53 |  |  |  | 15 |  |  |  | 42 |
Decrease related to settlements with tax authorities and lapse of applicable statutes of limitations |  |  | (395 | ) |  |  | (15 | ) |  |  | (31 | )
Other |  |  | 29 |  |  |  | 14 |  |  |  | 1 |
Balance at the end of the year |  | $ | 449 |  |  | $ | 651 |  |  | $ | 638 |

X
- Definition Domestic And Foreign Income Tax Expense Benefit Table [Text Block] + References No definition available. + Details
Name: | teva_DomesticAndForeignIncomeTaxExpenseBenefitTableTextBlock
Namespace Prefix: | teva_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Schedule of deferred tax assets and liabilities by report caption. + References No definition available. + Details
Name: | teva_ScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionTableTextBlock
Namespace Prefix: | teva_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2 + Details
Name: | us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 + Details
Name: | us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of income before income tax between domestic and foreign jurisdictions. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details
Name: | us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the change in unrecognized tax benefits. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 217 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A + Details
Name: | us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration